Anselamimab
AL Amyloidosis
Alexion Pharmaceuticals, Inc.monoclonal_antibodyPhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the AL Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE St. Olavs Hospital | Phase 3 | BB |
Cyclophosphamide Alexion Pharmaceuticals, Inc. | Phase 3 | B |
Florbetaben University of Zurich | Phase 3 | B |
Selinexor Washington University School of Medicine | Phase 2 | B |
Bortezomib Alexion Pharmaceuticals, Inc. | Phase 3 | B |
View all 22 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →